DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,126 filers reported holding DANAHER CORPORATION in Q2 2017. The put-call ratio across all filers is 0.51 and the average weighting 0.5%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,151,640 | +459.4% | 24,795 | +441.1% | 0.05% | +410.0% |
| Q2 2023 | $1,099,680 | -54.1% | 4,582 | -51.8% | 0.01% | -52.4% |
| Q1 2023 | $2,397,405 | -16.1% | 9,512 | -11.6% | 0.02% | -16.0% |
| Q4 2022 | $2,856,185 | -4.1% | 10,761 | -6.6% | 0.02% | -10.7% |
| Q3 2022 | $2,977,000 | +45.8% | 11,527 | +43.1% | 0.03% | +40.0% |
| Q2 2022 | $2,042,000 | -32.1% | 8,053 | -21.4% | 0.02% | -39.4% |
| Q1 2022 | $3,006,000 | -9.4% | 10,248 | +1.7% | 0.03% | -10.8% |
| Q4 2021 | $3,317,000 | +5.7% | 10,080 | -2.2% | 0.04% | +23.3% |
| Q3 2021 | $3,138,000 | +7.3% | 10,308 | -5.4% | 0.03% | +15.4% |
| Q2 2021 | $2,924,000 | +21.7% | 10,897 | +2.1% | 0.03% | +13.0% |
| Q1 2021 | $2,402,000 | +3.0% | 10,672 | +1.6% | 0.02% | -11.5% |
| Q4 2020 | $2,333,000 | -13.7% | 10,502 | -16.3% | 0.03% | -35.0% |
| Q3 2020 | $2,703,000 | -22.0% | 12,549 | -36.0% | 0.04% | -13.0% |
| Q2 2020 | $3,466,000 | -1.1% | 19,601 | -22.6% | 0.05% | -14.8% |
| Q1 2020 | $3,506,000 | -32.6% | 25,331 | -25.3% | 0.05% | +31.7% |
| Q4 2019 | $5,204,000 | -1.2% | 33,905 | -7.0% | 0.04% | 0.0% |
| Q3 2019 | $5,265,000 | +196.1% | 36,455 | +193.0% | 0.04% | +215.4% |
| Q2 2019 | $1,778,000 | -71.2% | 12,443 | -73.3% | 0.01% | -70.5% |
| Q1 2019 | $6,163,000 | +10.6% | 46,683 | -13.6% | 0.04% | +2.3% |
| Q4 2018 | $5,574,000 | -20.3% | 54,060 | -16.0% | 0.04% | -6.5% |
| Q3 2018 | $6,996,000 | +3.4% | 64,385 | -6.1% | 0.05% | +4.5% |
| Q2 2018 | $6,763,000 | +15.0% | 68,537 | +14.1% | 0.04% | -6.4% |
| Q1 2018 | $5,881,000 | +40.0% | 60,062 | +32.7% | 0.05% | +62.1% |
| Q4 2017 | $4,202,000 | +9.2% | 45,262 | +0.9% | 0.03% | +7.4% |
| Q3 2017 | $3,848,000 | -67.9% | 44,860 | -68.4% | 0.03% | -67.9% |
| Q2 2017 | $11,972,000 | -3.8% | 141,858 | -11.3% | 0.08% | -8.7% |
| Q4 2016 | $12,451,000 | -51.7% | 159,948 | -51.3% | 0.09% | -56.2% |
| Q3 2016 | $25,756,000 | -32.7% | 328,563 | -18.6% | 0.21% | -46.8% |
| Q1 2016 | $38,272,000 | +34.8% | 403,462 | +21.1% | 0.40% | +1216.7% |
| Q3 2015 | $28,388,000 | – | 333,155 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |